## Subasumstat

Cat. No.:	HY-111789	HY-111789			
CAS No.:	1858276-04	1858276-04-6			
Molecular Formula:	C <sub>25</sub> H <sub>28</sub> CIN <sub>5</sub> O <sub>5</sub> S <sub>2</sub>				
Molecular Weight:	578.1				
Target:	E1/E2/E3 Enzyme				
Pathway:	Metabolic Enzyme/Protease				
Storage:	Powder	-20°C	3 years		
	In solvent	-80°C	6 months		
		-20°C	1 month		

®

MedChemExpress

### SOLVENT & SOLUBILITY

In Vitro	DMSO : 16.67 mg/mL (28.84 mM; ultrasonic and warming and heat to 80°C)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	1.7298 mL	8.6490 mL	17.2980 mL		
		5 mM	0.3460 mL	1.7298 mL	3.4596 mL		
	10 mM	0.1730 mL	0.8649 mL	1.7298 mL			
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.32 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.32 mM); Suspended solution; Need ultrasonic						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.32 mM); Clear solution						

BIOLOGICAL ACTIVITY				
Description	Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities <sup>[1][2]</sup> .			
IC <sub>50</sub> & Target	SUMOylation <sup>[1]</sup> .			
In Vitro	Subasumstat (TAK-981) is able to increase the production of type 1 IFN, thereby increasing type 1 IFN-mediated signaling, activating innate effector cells and enhancing the antitumor innate immune responses <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

# Product Data Sheet

NH

но

\_\_\_\_\_́NH₂

С

In Vivo

A single sub-cutaneous injection of Subasumstat (TAK-981) in naive Balb/c mice at the brachial lymph nodes induces activation of DCs<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **CUSTOMER VALIDATION**

- Nat Microbiol. 2022 Nov 14.
- J Clin Invest. 2022 May 2;132(9):e152383.
- EMBO Mol Med. 2023 Jul 24;e16431.
- Cell Death Dis. 2023 Feb 21;14(2):147.
- J Biol Chem. 2023 Sep 22;105280.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Sumoylation inhibitor TAK-981.

[2]. TAK-981.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA